The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Psoriasis — Biologic Therapy

Targeted biologic agents (TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitor) for moderate-to-severe plaque psoriasis, psoriatic arthritis, and treatment-resistant disease offering high efficacy with PASI 90/100 responses and improved quality of life.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Psoriasis — Biologic Therapy?

Biologic therapy revolutionized treatment of moderate-to-severe psoriasis by targeting specific immune pathways involved in disease pathogenesis. Indications include psoriasis affecting >10% body surface area, special locations (face, palms/soles, genitalia, scalp), psoriatic arthritis, inadequate response to topical therapy and phototherapy, and contraindications/intolerance to conventional systemic agents (methotrexate, cyclosporine, acitretin).

Mechanisms of action include TNF-α inhibition (etanercept fusion protein, infliximab/adalimumab/certolizumab/golimumab monoclonal antibodies), IL-17A blockade (secukinumab, ixekizumab), IL-17 receptor blockade (brodalumab), dual IL-17A/F blockade (bimekizumab), IL-23 p19 subunit blockade (guselkumab, risankizumab, tildrakizumab), and IL-12/23 p40 blockade (ustekinumab). Newer IL-23 inhibitors offer extended dosing intervals (every 8-12 weeks).

Efficacy outcomes show PASI 90 (90% improvement in Psoriasis Area Severity Index) in 60-90% and PASI 100 (complete clearance) in 30-60% of patients depending on agent. Selection considers psoriasis severity, comorbidities (psoriatic arthritis, IBD, multiple sclerosis), patient preferences, prior therapy failures, infection risk, and access. Pre-biologic screening includes tuberculosis (PPD/IGRA), hepatitis B/C, HIV, and pregnancy assessment.

Symptoms

Plaque psoriasis with PASI score >10 or BSA >10%
Psoriasis affecting special sites: face, scalp, palms/soles, nails, genitals
Psoriatic arthritis with peripheral arthritis, dactylitis, enthesitis, or spondylitis
Failure or intolerance to conventional systemic therapy
Erythrodermic or pustular psoriasis (severe variants)
Significant impact on quality of life despite topical therapy
Inflammatory comorbidities (IBD, uveitis) suggesting biologic therapy benefit

Risk Factors

Active or recent serious infection (relative contraindication)
Latent tuberculosis requiring treatment before biologic initiation
Hepatitis B/C reactivation risk (especially TNF inhibitors)
Heart failure (TNF inhibitors contraindicated in NYHA III-IV)
Demyelinating disease history (avoid TNF inhibitors)
Inflammatory bowel disease (avoid IL-17 inhibitors, may worsen IBD)
Pregnancy planning (most biologics avoided, certolizumab acceptable)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Moderate-to-severe psoriasis not controlled with topical therapy
  • Psoriasis with significant impact on quality of life or work
  • Psoriatic arthritis with active joint inflammation
  • Special location psoriasis (face, palms/soles, genitals) refractory to therapy
  • Failure of conventional systemic therapy or significant side effects
  • Erythrodermic or pustular psoriasis requiring urgent treatment
  • Considering biologic initiation for screening and education

Treatment Methods

01
Pre-biologic workup: complete blood count, liver/renal function, hepatitis B/C, HIV, tuberculosis screening (PPD or IGRA), pregnancy test, vaccination review
02
Biologic selection based on psoriasis subtype, comorbidities (especially psoriatic arthritis, IBD), patient preferences, and access
03
TNF-α inhibitor (adalimumab, etanercept, infliximab, certolizumab) for psoriasis with psoriatic arthritis
04
IL-17 inhibitor (secukinumab, ixekizumab, bimekizumab) for rapid skin clearance and PsA but avoid in IBD
05
IL-23 inhibitor (guselkumab, risankizumab, tildrakizumab) for sustained skin clearance with extended dosing
06
Monitoring: clinical response (PASI, DLQI), injection site reactions, infections (especially upper respiratory), tuberculosis surveillance, periodic laboratory monitoring
07
Long-term management: dose optimization, switching biologics for inadequate response or loss of efficacy, vaccination updates, comorbidity screening

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.